Project Grant R01CA289574
Award Date
5/3/24
Completion Date
4/30/29
Dollars Obligated
$2.8M
Federal Agency
National Cancer Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Durham, NC 27708, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $169,344 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant period runs from September 1, 2024 to August 31, 2026. The purpose of this grant is to use single-cell and spatial multi-omics techniques to better understand the molecular mechanisms underlying the dysfunction of adoptive T cell therapy (ACT) against pancreatic cancer. The research aims to: 1) Identify...
This three-year, $3,024,000 project grant from the National Institutes of Health Trans-NIH Research Support program will fund research at Massachusetts General Hospital to understand the epigenetic mechanisms governing CD8 T cell fate decisions in tumor microenvironments. Using loss-of-function and gain-of-function approaches for enhancer editing, the researchers aim to identify how, when, and where CD8 T cell commitment occurs in vivo, initially focusing on exhausted CD8 T cells in melanoma and...
This $169,500 federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS) (CFDA 93.350) aims to comprehensively identify metabolic enzymes that control the generation of TCF1+ progenitor CD8+ T cells, which are critical for effective anti-tumor immune responses. The key products and services to be delivered under this 2-year award include: 1) Conducting a CRISPR/Cas9 screen to identify metabolic enzymes regulating TCF1+ progenitor cell generation across...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $483,041 in funding to Baylor College of Medicine to engineer transcription factors that can improve the persistence and effector function of therapeutic T cells for cancer immunotherapy. The key goals are to: 1) understand the molecular mechanisms of transcription factors regulating T-cell exhaustion, 2) increase resistance to T-cell dysfunction through systematic...
The National Cancer Institute awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF) to develop a bispecific T cell engager targeting the tumor-specific antigen ALPPL2. The $544,866 grant aims to generate and optimize ALPPL2-targeted bispecific T cell engagers, evaluate their tumor-specific cytotoxicity and cytokine release, and identify a lead candidate for clinical translation. UCSF, a prominent...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $402,600.00 to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP200 protein for the treatment of acute myeloid leukemia (AML). The key objectives are to: Test the efficacy and safety of the U5 snRNP200-targeted CAR T-cells, including engineered versions that secrete IL-18, in preclinical AML models....
The National Institutes of Health (NIH) Office of the Director awarded a $1,602,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant, effective September 1, 2024 through August 31, 2027, aims to develop and optimize a new class of Epigenetic Reprogramming Factors (ERFs) to enhance the fitness of Chimeric Antigen Receptor (CAR) T cells for improved treatment of both liquid and solid tumors. The...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) supports the Fred Hutchinson Cancer Center in Seattle, Washington to develop a novel cancer immunotherapy approach using engineered CD4+ T cells. The research aims to overcome treatment resistance in solid tumors, such as melanoma, by leveraging CD4+ T cells to activate other immune cells in the tumor microenvironment. The researchers plan to isolate and expand tumor-specific...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a precision adoptive T cell therapy approach for the treatment of pediatric high-grade gliomas (HGG). The $474,656 grant, awarded on August 12, 2024, will support the development and evaluation of a "next-generation" immunotherapy that uses patient-specific antigen profiling, a gene enrichment strategy, and selective expansion of tumor-reactive T cells. The goal is to...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $207,900 to The Leland Stanford Junior University (Stanford University) to develop a three-cell synthetic immunotherapy system. The research aims to engineer T cells, natural killer (NK) cells, and macrophages to express chimeric antigen receptors (CARs) and synthetic...